Kyverna Therapeutics
D

KYTX

5.38000
USD
0.11
(2.09%)
قبل الجلسة·5.22000USD-0.16000(-2.97%)
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
3,246
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
332,717,729

العنوان: Kyverna Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.